Analysis in early stage triple-negative breast cancer treated with mastectomy without adjuvant radiotherapy: Patterns of failure and prognostic factors

Cancer

Volumn 119, Issue 13, 2013, Pages 2366-2374

  Chen, Xingxing ^a,b   Yu, Xiaoli ^a,b   Chen, Jiayi ^a,b   Zhang, Zhen ^a   Tuan, Jeffrey ^c   Shao, Zhimin ^a   Guo, Xiaomao ^a,b   Feng, Yan ^a,b  

^a FUDAN UNIVERSITY   (China)

^b FUDAN UNIVERSITY SHANGHAI CANCER CENTER   (China)

^c DIVISION OF MEDICAL ONCOLOGY   (Singapore)

Author keywords

breast cancer; locoregional recurrence; mastectomy; molecular subtype; pattern of failure; postmastectomy radiotherapy; risk factors; triple negative

Indexed keywords

ANTHRACYCLINE DERIVATIVE; CYCLOPHOSPHAMIDE; FLUOROURACIL; METHOTREXATE;

ADULT; ARTICLE; BREAST RECONSTRUCTION; CANCER CHEMOTHERAPY; CANCER GRADING; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER RECURRENCE; DISTANT METASTASIS; EARLY CANCER; FEMALE; FOLLOW UP; HUMAN; LYMPH NODE DISSECTION; LYMPH VESSEL METASTASIS; MAJOR CLINICAL STUDY; MASTECTOMY; POSTMASTECTOMY RADIOTHERAPY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; TREATMENT FAILURE; TRIPLE NEGATIVE BREAST CANCER;

ADULT; AGED; BREAST NEOPLASMS; CHINA; FEMALE; HUMANS; INCIDENCE; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MASTECTOMY, MODIFIED RADICAL; MIDDLE AGED; MULTIVARIATE ANALYSIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RADIOTHERAPY, ADJUVANT; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; RISK FACTORS; TREATMENT FAILURE; TUMOR MARKERS, BIOLOGICAL;

EID: 84879106413     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.28085     Document Type: Article

References (29)

1. Sorlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 2001; 98: 10869-10874.
2. Dent R, Trudeau M, Pritchard KI, et al. Triple-negative breast cancer: clinical features and patterns of recurrence. Clin Cancer Res. 2007; 13 (15 pt 1): 4429-4434.
3. Overgaard M, Hansen PS, Overgaard J, et al. Postoperative radiotherapy in high-risk premenopausal women with breast cancer who receive adjuvant chemotherapy. Danish Breast Cancer Cooperative Group 82b Trial. N Engl J Med. 1997; 337: 949-955.
4. Ragaz J, Olivotto IA, Spinelli JJ, et al. Locoregional radiation therapy in patients with high-risk breast cancer receiving adjuvant chemotherapy: 20-year results of the British Columbia randomized trial. J Natl Cancer Inst. 2005; 97: 116-126.
5. Clarke M, Collins R, Darby S, et al. Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: an overview of the randomised trials. Lancet. 2005; 366: 2087-2106.
6. Carlson RW, Anderson BO, Burstein HJ, et al. Breast cancer. J Natl Compr Canc Netw. 2005; 3: 238-289.
7. Recht A, Edge SB, Solin LJ, et al. Postmastectomy radiotherapy: clinical practice guidelines of the American Society of Clinical Oncology. J Clin Oncol. 2001; 19: 1539-1569.
8. Favourable and unfavourable effects on long-term survival of radiotherapy for early breast cancer: an overview of the randomised trials. Early Breast Cancer Trialists' Collaborative Group. Lancet. 2000; 355: 1757-1770.
9. Overgaard M, Nielsen HM, Overgaard J,. Is the benefit of postmastectomy irradiation limited to patients with 4 or more positive nodes, as recommended in international consensus reports? A subgroup analysis of the DBCG 82 b&c randomized trials. Radiother Oncol. 2007; 82: 247-253.
10. Kyndi M, Sorensen FB, Knudsen H, Overgaard M, Nielsen HM, Overgaard J,. Estrogen receptor, progesterone receptor, HER-2, and response to postmastectomy radiotherapy in high-risk breast cancer: the Danish Breast Cancer Cooperative Group. J Clin Oncol. 2008; 26: 1419-1426.
11. Voduc KD, Cheang MC, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H,. Breast cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010; 28: 1684-1691.
12. Kwon JH, Kim YJ, Lee KW, et al. Triple negativity and young age as prognostic factors in lymph node-negative invasive ductal carcinoma of 1 cm or less [serial online]. BMC Cancer. 2010; 10: 557.
13. Cancello G, Maisonneuve P, Rotmensz N, et al. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes. Breast Cancer Res Treat. 2011; 127: 713-720.
14. Abdulkarim BS, Cuartero J, Hanson J, Deschenes J, Lesniak D, Sabri S,. Increased risk of locoregional recurrence for women with T1-T2N0 triple-negative breast cancer treated with modified radical mastectomy without adjuvant radiation therapy compared with breast-conserving therapy. J Clin Oncol. 2011; 29: 2852-2858.
15. Yin WJ, Lu JS, Di GH, et al. Clinicopathological features of the triple-negative tumors in Chinese breast cancer patients. Breast Cancer Res Treat. 2009; 115: 325-333.
16. Sharma R, Bedrosian I, Lucci A, et al. Present-day locoregional control in patients with T1 or T2 breast cancer with 0 and 1 to 3 positive lymph nodes after mastectomy without radiotherapy. Ann Surg Oncol. 2010; 17: 2899-2908.
17. Truong PT, Olivotto IA, Kader HA, Panades M, Speers CH, Berthelet E,. Selecting breast cancer patients with T1-T2 tumors and 1 to 3 positive axillary nodes at high postmastectomy locoregional recurrence risk for adjuvant radiotherapy. Int J Radiat Oncol Biol Phys. 2005; 61: 1337-1347.
18. Millar EK, Graham PH, O'Toole SA, et al. Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a 5-biomarker panel. J Clin Oncol. 2009; 27: 4701-4708.
19. Trovo M, Durofil E, Polesel J, et al. Locoregional failure in early-stage breast cancer patients treated with radical mastectomy and adjuvant systemic therapy: which patients benefit from postmastectomy irradiation [serial online]? Int J Radiat Oncol Biol Phys. 2012; 83: e153-e157.
20. Wang SL, Li YX, Song YW, et al. Triple-negative or HER2-positive status predicts higher rates of locoregional recurrence in node-positive breast cancer patients after mastectomy. Int J Radiat Oncol Biol Phys. 2011; 80: 1095-1101.
21. Fisher ER, Anderson S, Redmond C, Fisher B,. Pathologic findings from the National Surgical Adjuvant Breast Project protocol B-06. Ten-year pathologic and clinical prognostic discriminants. Cancer. 1993; 71: 2507-2514.
22. Rakha EA, Morgan D, Macmillan D,. The prognostic significance of early stage lymph node positivity in operable invasive breast carcinoma: number or stage. J Clin Pathol. 2012; 65: 624-630.
23. Truong PT, Olivotto IA, Speers CH, Wai ES, Berthelet E, Kader HA,. A positive margin is not always an indication for radiotherapy after mastectomy in early breast cancer. Int J Radiat Oncol Biol Phys. 2004; 58: 797-804.
24. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer subtypes. J Clin Oncol. 2010; 28: 3271-3277.
25. Yildirim E, Berberoglu U,. Can a subgroup of node-negative breast carcinoma patients with T1-2 tumor who may benefit from postmastectomy radiotherapy be identified? Int J Radiat Oncol Biol Phys. 2007; 68: 1024-1029.
26. Yildirim E, Berberoglu U,. Local recurrence in breast carcinoma patients with T(1-2) and 1-3 positive nodes: indications for radiotherapy. Eur J Surg Oncol. 2007; 33: 28-32.
27. Parikh RR, Housman D, Yang Q, Toppmeyer D, Wilson LD, Haffty BG,. Prognostic value of triple-negative phenotype at the time of locally recurrent, conservatively treated breast cancer. Int J Radiat Oncol Biol Phys. 2008; 72: 1056-1063.
28. Montagna E, Bagnardi V, Rotmensz N, et al. Breast cancer subtypes and outcome after local and regional relapse. Ann Oncol. 2012; 23: 324-331.
29. Olivotto IA, Truong PT, Chua B,. Postmastectomy radiation therapy: who needs it? J Clin Oncol. 2004; 22: 4237-4239.